Physician profile
Van C Reeder
NPI 1871678284
$1,804.39
in general payments reported to CMS, 2019-2025
19 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $25.51 · 2021: $60.55 · 2022: $557 · 2023: $347 · 2024: $263 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $546.24 | 2022-2025 | |
| Pfizer INC. | $242.37 | 2022-2025 | |
| Abbott Laboratories | $201.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.42 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $126.08 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $95.21 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $78.71 | 2022-2023 | Verquvo |
| Amgen INC. | $59.26 | 2022-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $55.46 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.47 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $37.74 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $36.50 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $24.42 | 2023 | Optimizer |
| Angiodynamics, INC. | $19.92 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.66 | 2025 | Amvuttra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.32 | 2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $15.18 | 2022 | |
| Amarin Pharma, INC. | $13.17 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.96 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.